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protein synthesis in human cancer cells.
In Fall 2011,Dr.Marintcheva was
awarded a CART Faculty and Librarian
Research Grant to take the first steps in
this ambitious project.To humility and
determination,we might add patience:
this Spring,Dr.Marintcheva took time
to explain her research and teaching
to this scientific layman.
“Cancer is a collection of many different
diseases characterized by uncontrolled
growth, such as we see in tumors and
leukemia,” she explains.All cells are
built from proteins.But these cells don’t
follow the normal rules; they have a
greater demand for proteins than
normal cells and they divide non-stop.
“Our line of thinking is this: if we can
inhibit protein synthesis, cancer cells
will be at a disadvantage.”This is similar
in logic to the science on which radia-
tion and chemotherapy is based,but
those regimens are rooted in genetic
information,not protein formation.
Moreover,new cancer cells can be
generated because of the damage caused
by these routine treatments.
The novelty of Dr.Marintcheva’s work
is that it targets protein behavior as it
relates to synthesis of new proteins.
More specifically,her work focuses on
the unique properties of two proteins
with“floppy tails”whose interactions
are a weak link in protein synthesis.
“If we can find a way to disrupt the
bindings, then we can slow down the
process of synthesis,” and, in turn, slow
the growth of cancer cells in tumors.
“It’s not a magic bullet,” she notes,“but
it is a step on the road toward fighting
the disease.”
Still, she admits, that’s a very long road.
Scientific research applicable to abating
cancer occupies scientists’ time and
resources more than ever before,but
their work is necessarily piecemeal and,
often,disparate.“Everything is done in
small steps,”Dr.Marintcheva notes,
“and there is a lot of trial and error.”
One running joke among scientists
invokes etymology.“What we do is
called re-search,because we have to
search and search, again and again.”
Dr.Marintcheva’s project will begin
in earnest this summer,when she under-
takes her first task: to develop a frame-
work or“assay”– a workable system,
in her words – for testing chemical
compounds to see if and how they
interfere with protein synthesis.Her
work will be done at the laboratories at
Boston University,where her research
collaborator (and husband),Dr.Assen
Marintchev,works as a biologist at
BUMedical School.Their collaboration
is typical, in some ways,of the larger
enterprise of scientific research.“No
one researcher ever has all the equip-
ment or expertise she needs,” she says.
“We complement one another.That’s
how the sciences work.”Their planned
method is called fluorescence polarization:
an approach that allows the researcher to
monitor protein interaction by tagging
protein tails,which makes visible and
measurable their propensity to bind.
“Once we know how nature behaves,
we can move forward to the second
step,which is performing the actual
chemical screen.”
For Dr.Marintcheva,who has just
completed her fourth year as a professor





“Modern science has been a voyageinto the unknown,with a lesson inhumility waiting at every stop,” late
astrophysicist Carl Sagan told us in an oft-quoted
passage from his 1994 best-seller Pale Blue Dot.
“Many passengers would rather have stayed home.”
Many perhaps would have,but not Bridgewater
State virologist Boriana Marintcheva.Humility and
determination, it seems, are two essential items in
her professional toolkit and fuel for her own current




challenge in part because, for her, it is
still relatively new terrain.Trained in
biochemistry and microbiology at Sofia
University in her native Bulgaria, she
moved to the United States in 1996
to do doctoral work in virology at the
University of Connecticut-Health
Center Farmington.As a post-doctoral
fellow at Harvard (2003-08), she worked
on protein-protein interactions in
bacterial viruses involving“floppy tails.”
Beyond novelty is the daunting chal-
lenge of time.Given BSU teaching
schedules, summer is the only time she
can realistically set aside for this project.
Even then, she knows well that in scien-
tific research, results are never guaran-
teed.“When you work with living
systems,” she cautions,“you must build
room for surprises into the framework.”
Experiments rarely work on the first try
and at times that actual results are differ-
ent from the theoretical expectations.
But every experiment can lead
to new questions and lines of pursuit
toward solving the problem.
And laboratory experience is never
wasted;much of what Dr.Marintcheva
confronts in and learns from her
research off campus will most certainly
find its way into her teaching.
“Whatever I read for research, I inte-
grate into my upper-level classes at
Bridgewater State,” she notes, adding
that cancer is a topic that she addresses
in her current capstone course for
seniors.This integration is also evident
in Dr.Marintcheva’s work as a mentor
of undergraduate research at BSU. In
Spring semester 2012, six of her research
students traveled to present their
work involving bacterial viruses at the
National Council on Undergraduate
Research annual conference in Utah.
In her four years at the University,
she has directed 11 undergraduate
student research projects, and at least
two of those students have gone on
to graduate study.
In all of this she credits her colleagues
in the Biological Sciences Department
for articulating a philosophy that
teaching and research are not separate
endeavors at BSU.The department
offers its students several research-based
courses that are intrinsically rich,but
also give those inclined to pursue gradu-
ate study a demonstrable record of
research experience that betters their
chances for getting accepted at choice
schools.“I didn’t invent the wheel,” she
says.“The commitment of the Depart-
ment to undergraduate research makes
all that possible.”
Humility.Determination.Patience.
These attributes have long been recog-
nized as traits among good university
teachers, but they are essential for
scientific researchers, too.Bridgewater
State’s Boriana Marintcheva is a case
in point.“I never had the goal to do
cancer research,per se.But the things
that I had done before this project tell
me that I can at least attempt it and
hope for the best.”
Andrew C.Holman is Editor of
Bridgewater Review.
Overall Design of the ProposedAssay
This three-phase experiment tests the interaction of human proteins and the
propensity of protein tails to bind and disrupt binding. In Phase A, a purified human
protein, (eIF5B, or eukaryrotic initiation factor 5B) depicted by a blue circle, is
mixed with the tail of a second human protein (eIF5) indicated by the black curvy
line, that is attached to a green fluorescent label (depicted with a green oval).
The result of this is seen in Phase B: the interaction of eIF5B and eIF5 tail creates
a stable complex (blue circle with attached black line and green oval). In Phase C,
when the tail of a third human protein (eIF1A) depicted in the red curvy line is
added to complex, the eIF1A (red) tail outcompetes the attached eIF5 (black)
tail, thus disrupting the initially formed complex. In the described scenario, the
molecule depicted by red wavy line acts to inhibit the expected protein interaction
in A and B. Any small molecule that can mimic the action of the eIF1A tail
disrupting the interaction between eIF5B and eIF5 would make a great candidate
for an anti-cancer drug since it would be able to disrupt protein synthesis, thus
slowing down cancer growth.
